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Purpose of the study
To assess the antiviral efficacy of a triple nucleoside
reverse transcriptase inhibitor (NRTI) regimen as mainte-
nance therapy, after successful induction with a dual NRTI
and protease inhibitor (PI) combination.
Methods
Randomized, open-label, multicenter, 96-week compara-
tive study. Main inclusion criteria: antiretroviral therapy
(ART) naïve patients, CD4 ≤350 cells/μL, HIV-1 RNA con-
centrations (VL) > 30,000 copies/mL. Exclusion criteria
included predefined abnormal values of fasting glucose,
triglycerides, LDL-cholesterol or LDL/HDL ratio. Patients
were randomized after they had reached VL < 50 c/mL on
two consecutive occasions between 12 and 24 weeks after
the start of a BID zidovudine/lamivudine and BID lopina-
vir/ritonavir combination. Eligible subjects switched to
abacavir/lamivudine/zidovudine (TZV) bid or continued
the PI-containing regimen. Primary end-point at week 96:
proportion of subjects with VL < 400 c/mL. Here, we
present the 48-week interim data with virological failure
VL > 50 c/mL.
Summary of results
207 patients had similar baseline (BL) characteristics:
mean age 41 years, 87% male, median CD4 180 cells/
mm3 (range 10–440), median VL 155,000 c/mL (900–
28300000). A total of 118 subjects (57%) met randomi-
zation criteria. Of all BL data, only VL differed signifi-
cantly between dropouts and randomized subjects
(median 253,000 c/mL versus 118,500 c/mL, p = 0.006).
After 14 weeks, 21 subjects were randomized, after 20
weeks: 40 subjects, and after 26 weeks: 57 subjects. Sixty
subjects were allocated to TZV switch, and 58 subjects to
continue NRTIs/PI. At 48 weeks follow-up after BL, there
were no significant differences between CD4 cells in the
TZV arm (median 340 cells/mm3), and the NRTIs/PI arm
(397 cells/mm3). VL results were similar; there were two
virological failures (3%) in the TZV group (1,480 person-
weeks) and seven (12%) in the NRTIs/PI-group (1,475
person-weeks) after 48 weeks of therapy (Log Rank test; p
= 0.13).
Conclusion
TZV as maintenance therapy after induction with NRTIs/
PI in previously antiretroviral naïve patients shows an
antiviral activity comparable to continuation of a PI-based
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regimen at 48 weeks interim analysis. Final analysis of the
data at week 96 has to be awaited to further evaluate the
efficacy of TZV maintenance ART.Page 2 of 2
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